Hepati tis web study Hepati tis web study Duration and Dose Finding Peginterferon alfa- 2a + Ribavirin Phase 3 Treatment Naïve, Chronic HCV Randomized study of low-dose versus weight based ribavirin and 24 versus 48 weeks of therapy Hadziyannis SJ, et. al. Ann Intern Med. 2004;140:346-55.
7
Embed
Duration and Dose Finding Peginterferon alfa-2a + Ribavirin
Phase 3. Treatment Naïve, Chronic HCV. Duration and Dose Finding Peginterferon alfa-2a + Ribavirin . Randomized study of low-dose versus weight based ribavirin and 24 versus 48 weeks of therapy. Hadziyannis SJ, et. al. Ann Intern Med. 2004;140:346-55. . - PowerPoint PPT Presentation
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Hepatitisweb study
Hepatitisweb study
Duration and Dose Finding Peginterferon alfa-2a + Ribavirin
Phase 3
Treatment Naïve, Chronic HCV
Randomized study of low-dose versus weight based ribavirin and 24 versus 48 weeks of therapy
Hadziyannis SJ, et. al. Ann Intern Med. 2004;140:346-55.
Hepatitisweb study
*Ribavirin dose: Ribavirin 1000 mg/day for Wt <75 kg, 1200 mg/day for Wt ≥75 kg
Peginterferon alfa-2a + Ribavirin for Chronic HCVTreatment Duration and Ribavirin Dose
• Study- Randomized, double-blind trial, with 2 x 2 factorial design
• Subjects- N = 1311 with chronic hepatitis C (1284 treated)- Treatment naïve adult patients; 58% genotype 1 - Serum ALT above upper limit of normal x prior 6 months
Source: Hadziyannis SJ, et. al. Ann Intern Med. 2004;140:346-55.
Peginterferon alfa-2a + Ribavirin for Chronic HCVTreatment Duration and Ribavirin Dose
SVR24
SVR24
SVR24
SVR24
Hepatitisweb study
Genotype 1 Genotypes 2 or 30
20
40
60
80
100
29
84
42
81
41
79
52
80
PEG + RBV (low dose) x 24 weeks PEG + RBV (weight-based dose) x 24 weeks
PEG + RBV (low dose) x 48 weeks PEG + RBV (weight-based dose) x 48 weeks
Genotype
Patie
nts
with
SVR
(%)
Peginterferon alfa-2a + Ribavirin for Chronic HCVTreatment Duration and Ribavirin Dose
SVR24 Rates, by Regimen
Source: Hadziyannis SJ, et. al. Ann Intern Med. 2004;140:346-55.
n = 101 n = 118 n = 250 n = 271 n = 96 n = 144 n = 99 n = 153
Hepatitisweb study
All Patients Low Viral Load_x000d_(≤2 mil-
lion)
High Viral Load_x000d_(>2 mil-
lion)
0
20
40
60
80
10084 85 8481 83 8079
88
7480 77
82
Peginterferon + Ribavirin (low dose) x 24 weeks Peginterferon + Ribavirin (weight-based dose) x 24 weeks Peginterferon + Ribavirin (low dose) x 48 weeks Peginterferon + Ribavirin (weight-based dose) x 48 weeks
Patie
nts
with
SVR
(%)
Peginterferon alfa-2a + Ribavirin for Chronic HCVTreatment Duration and Ribavirin Dose
Rates of SVR with Different Peginterferon + Ribavivirn Regimens
Source: Hadziyannis SJ, et. al. Ann Intern Med. 2004;140:346-55.
(≤ 2 x 106 copies/ml) (> 2 x 106 copies/ml)
Hepatitisweb studySource: Hadziyannis SJ, et. al. Ann Intern Med. 2004;140:346-55.
Peginterferon alfa-2a + Ribavirin for Chronic HCVTreatment Duration and Ribavirin Dose
Conclusion: “Treatment with peginterferon-alpha2a and ribavirin may be individualized by genotype. Patients with HCV genotype 1 require
treatment for 48 weeks and a standard dose of ribavirin; those with HCV genotypes 2 or 3 seem to be adequately treated with a low dose of ribavirin for 24 weeks.”
Hepatitisweb study
Hepatitisweb study
This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects.
Hepatitis C Onlinewww.hepatitisc.uw.edu
Hepatitis Web Studyhttp://depts.washington.edu/hepstudy/
Funded by a grant from the Centers for Disease Control and Prevention.